Login to Your Account



Clinic Roundup


Wednesday, February 1, 2012

• Argos Therapeutics Inc., of Durham, N.C., presented a high resolution immune monitoring analysis of Phase II study AGS-003-006, testing Arcelis immunotherapy AGS-003 in combination with Sutent (sunitinib, Pfizer Inc.) in patients with advanced renal cell carcinoma (RCC), with results showing a statistically significant correlation between antitumor memory T-cell responses and overall survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription